Molecular basis of the urate transporter URAT1 inhibition by gout drugs.

ABSTRACT: Hyperuricemia is a condition when uric acid, a waste product of purine metabolism, accumulates in the blood¹. Untreated hyperuricemia can lead to crystal formation of monosodium urate in the joints, causing a painful inflammatory disease known as gout. These conditions are associated with many other diseases and affect a significant and increasing proportion of the population^2-4. The human urate transporter 1 (URAT1) is responsible for the reabsorption of ~90% of uric acid in the kidneys back into the blood, making it a primary target for treating hyperuricemia and gout⁵. Despite decades of research and development, clinically available URAT1 inhibitors have limitations because the molecular basis of URAT1 inhibition by gout drugs remains unknown⁵

SUBMITTER: Suo Y 

PROVIDER: S-EPMC11419087 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature